STOCK TITAN

Retractable Technologies Q3 operating loss widens to $4.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Retractable Technologies, Inc. (RVP) reported third-quarter 2026 net sales of $14.1 million, compared with $10.1 million a year earlier, while its operating loss widened to $4.1 million from $3.7 million. For the first nine months, net sales were $28.5 million versus $28.8 million, and the operating loss was $15.5 million versus $13.5 million. Net losses were $2.4 million for the quarter and $3.8 million for the nine months; the nine-month period included a $6.4 million gain on sale of equity securities.

Quarterly unit sales increased 64.0%, which the company attributed to EasyPoint® needle sales; it said product mix toward lower-average-selling-price products contributed to lower gross margin. Domestic production comprised 40.3% of units manufactured in the first nine months, when tariff expenses were approximately $318,000. The company said its April 2026 reduction in force resulted in cost savings.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter net sales rose to $14.1 million from $10.1 million.

Negative

  • Moderate pointQ3 operating loss widened to $4.1 million from $3.7 million.
  • Moderate pointNine-month operating loss widened to $15.5 million from $13.5 million.

Filing Explained

At September 30, cash and equivalents were $1,890,914, against third-quarter operating cash use of $248,232.

The release says most 2026 flu-season sales occurred in the third quarter, while 2025 flu-season sales were unusually high in the second quarter, affecting year-over-year comparability.

At September 30, 2026, cash and equivalents were $1,890,914, against third-quarter operating cash outflow of $248,232.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net sales $14.1 million Third quarter of 2026; compared with $10.1 million in the third quarter of 2025
Third-quarter operating loss $4.1 million Third quarter of 2026; compared with $3.7 million in the third quarter of 2025
Nine-month net sales $28.5 million First nine months of 2026; compared with $28.8 million in the same 2025 period
Nine-month operating loss $15.5 million First nine months of 2026; compared with $13.5 million in the same 2025 period
Third-quarter net loss $2.4 million Three months ended September 30, 2026
Nine-month net loss $3.8 million Nine months ended September 30, 2026
Gain on sale of equity securities $6.4 million First nine months of 2026
Tariff expenses Approximately $318,000 First nine months of 2026
gross margin financial
"lower gross margin"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
product mix financial
"changes in domestic and international product sales mix"
unrealized loss financial
"unrealized loss on debt and equity securities"
An unrealized loss is the drop in value of an investment that you still own — it's a loss on paper, not one you've locked in by selling. It matters to investors because it changes the reported worth of a portfolio and can influence decisions about holding, selling, or rebalancing; like seeing a car’s resale value fall while you still drive it, the loss only becomes permanent if you sell.
realized gain financial
"realized gain from the sale of equity securities"
Profit you actually lock in when you sell an investment: it’s the difference between what you received from the sale and what you originally paid. Like selling a used car for more than you paid, a realized gain turns a paper increase into cash that can be spent or reinvested, and it often creates tax obligations, so investors watch realized gains to understand true returns and potential tax impact.
average selling prices financial
"lower average selling prices compared to our domestic sales"
Average selling price (ASP) is the typical revenue a company receives for one unit of a product or service over a given period, calculated by dividing total sales revenue by the number of units sold. Like the average price you pay when buying many similar items, it shows whether a company is getting more or less for what it sells; investors watch ASP to gauge pricing power, product mix shifts, demand trends and how those factors will affect revenue and profit margins.
Third-quarter net sales $14.1 million Compared with $10.1 million in the third quarter of 2025
Third-quarter operating loss $4.1 million Compared with $3.7 million in the third quarter of 2025
Nine-month net sales $28.5 million Compared with $28.8 million in the same 2025 period
Nine-month operating loss $15.5 million Compared with $13.5 million in the same 2025 period

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did RVP report in third-quarter 2026 sales?

RVP reported $14.1 million in net sales for the third quarter of 2026, compared with $10.1 million for the same period in 2025.

What was RVP’s nine-month 2026 net loss, and did it include an investment gain?

RVP reported a $3.8 million net loss for the nine months ended September 30, 2026, including a $6.4 million gain on sale of equity securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000946563 0000946563 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 16, 2026

 

Retractable Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Texas   001-16465 75-2599762
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

511 Lobo Lane, Little Elm, Texas 75068-5295
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (972) 294-1010

 

None

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock RVP NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

  Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 8.01Other Events.

 

On November 16, 2026, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99, announcing results for the periods ended September 30, 2026.

 

Item 9.01Financial Statements and Exhibits.

 

(d)  Exhibits

 

99Press release announcing results for the periods ended September 30, 2026.

 

104Cover Page Interactive Date File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

DATE: November 16, 2026 RETRACTABLE TECHNOLOGIES, INC.
  (Registrant)
     
  BY: /s/ John W. Fort III
    JOHN W. FORT III
    VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER

 

 

 

 

Exhibit 99

 

RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026

 

LITTLE ELM, TEXAS, November 16, 2026 — Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4.1 million for the period, as compared to total net sales for the same period last year of $10.1 million and an operating loss of $3.7 million.  For the first nine months of the year, net sales were $28.5 million and operating losses were $15.5 million as compared to 2025 net revenues of $28.8 million and operating losses of $13.5 million.

 

In 2026, purchasing patterns have been more consistent with historical trends, with the majority of flu season sales occurring in the third quarter. In contrast, in 2025, flu season sales were unusually high in the second quarter, affecting comparability.

 

We continue to lessen the financial impact of tariffs by producing certain products domestically and strategically ordering certain products from our Chinese suppliers. Domestic production comprised 40.3% of the units manufactured during the first nine months of 2026. Additionally, a reduction in force in April 2026 has resulted in cost savings.

 

Our net losses for the three and nine months ended September 30, 2026 were $(2.4) million and $(3.8) million, respectively, including a $6.4 million gain on the sale of equity securities during the nine-month period ended September 30, 2026.

 

Retractable reports the following results of operations for the three and nine months ended September 30, 2026 and 2025, respectively. Further details concerning the results of operations, as well as other matters, are available in Retractable’s Form 10-Q filed on November 16, 2026 with the U.S Securities and Exchange Commission.

 

Comparison of Three Months Ended September 30, 2026 and September 30, 2025

 

Domestic net sales accounted for 90.3% and 91.1% of total net sales for the three months ended September 30, 2026 and 2025, respectively. Domestic net sales increased 38.9%, while domestic unit sales increased 59.5%, primarily due to the timing of EasyPoint® product orders from certain customers, which can fluctuate between periods based on customer purchasing patterns. The higher growth in unit sales relative to net sales reflects a shift in product mix, as EasyPoint® products, which traditionally carry a lower average selling price than syringe products, represented a greater proportion of domestic unit sales. Domestic unit sales represented 81.6% of total unit sales for the three months ended September 30, 2026, compared to 83.9% for the same period in 2025.

 

International net sales for the three months ended September 30, 2026 increased 52.2% compared to the same period in 2025. The increase in international sales was primarily driven by an increase in EasyPoint® needle sales. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

 

Overall, unit sales increased 64.0% due to an increase in EasyPoint® needle sales.

 

Cost of manufactured product increased 69.9% compared to the same period last year primarily due to an increase in units sold during the period. Royalty expense increased 29% due to the increase in gross sales.

 

Tariffs may impact our costs in future periods. Approximately $260 thousand was spent on tariff expenses in the third quarter of 2026. The continued reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

 

Operating expenses decreased 18.9% primarily due to lower gross wages in the Sales and Marketing department and lower donation and credit loss expenses within General and administrative expenses.

 

 

 

 

The loss from operations was $4.1 million for the three months ended September 30, 2026 compared to a loss from operations of $3.7 million in the three months ended September 30, 2025. The increase in loss from operations was primarily driven by lower gross margin in the current period, reflecting changes in domestic and international product sales mix, partially offset by lower operating expenses.

 

The unrealized loss on debt and equity securities was $150 thousand for the third quarter of 2026 due to the decreased market values of those securities. There was no realized gain or loss from the sale of debt and equity securities in the third quarter of 2026.

 

The provision for income taxes was $1.3 thousand for the three months ended September 30, 2026 and $1.7 thousand for the three months ended September 30, 2025.

 

Comparison of Nine Months Ended September 30, 2026 and September 30, 2025

 

Domestic net sales accounted for 86.2% and 87.1% of total net sales for the nine months ended September 30, 2026 and 2025, respectively. Domestic net sales decreased 2.1%, while domestic unit sales increased 6.4%, reflecting a shift in product mix toward EasyPoint® needles relative to syringes. As EasyPoint® needles traditionally have a lower average selling price than syringes, the change in product mix contributed to the decrease in domestic net sales. Domestic unit sales represented 76.6% of total unit sales for the nine months ended September 30, 2026, compared to 78.0% for the same period last year.

 

International net sales for the nine months ended September 30, 2026 increased 5.5% compared to the same period in 2025 primarily due to an increase in EasyPoint® sales. Traditionally, international sales carry lower average selling prices compared to our domestic sales. There remains uncertainty regarding the timing of future international orders.

 

Overall, unit sales increased 8.3%.

 

Cost of manufactured product increased 6.8% compared to the same period last year primarily due to an increase in units sold. The shift in product mix towards lower-margin products also contributed to the decrease in gross margin. Royalty expense remained consistent with the prior period.

 

Tariffs may impact our costs in future periods. Approximately $318 thousand was spent on tariff expenses in the first nine months of 2026. The continued reduction in tariff costs compared to prior periods is attributable to ongoing mitigation efforts, including strategic sourcing decisions and increased domestic production. These costs are included in Cost of manufactured product.

 

Operating expenses remained consistent with the prior period.

 

The loss from operations was $15.5 million compared to a loss of approximately $13.5 million for the same period last year. The increased loss from operations was primarily driven lower gross margin, reflecting changes in domestic and international product sales mix.

 

The unrealized loss on debt and equity securities was $137 thousand for the nine months ended September 30, 2026 due to the decreased market values of those securities. The realized gain from the sale of equity securities was $6.4 million in the first nine months of 2026.

 

The provision for income taxes was $5.0 thousand as compared to a benefit for income taxes of $289 thousand for the same period in 2025. The change is primarily due to a decrease in the net loss in the current period.

 

 

 

 

ABOUT RETRACTABLE

 

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.

 

For more information on Retractable, visit its website at www.retractable.com.

 

Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.

 

Factors that could cause or contribute to such differences include, but are not limited to: tariffs; oil prices; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.

 

Retractable Technologies, Inc.

John W. Fort III, 888-806-2626 or 972-294-1010

Vice President, Chief Financial Officer, and Chief Accounting Officer

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading